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Background/aim: To reveal the potential efficiency of high-flow oxygen therapy in acute pancreatitis complicated with acute respiratory
dysfunction compared with conventional oxygen therapy.
Materials and methods: We retrospectively analyzed 69 patients treated with high-flow oxygen or conventional oxygen therapy, then
compared the difference of prime and second outcomes between the two groups.
Results: The high-flow oxygen group had lower intubation rate (25.6% vs. 56.7%, p = 0.013) and longer median time to intubation
(64.25 h vs. 7.75 h, p < 0.001) compared with the conventional oxygen group. High-flow oxygen had a stronger effect on improving
dyspnea (87.2% vs. 56.7%, p = 0.006) and regression of respiratory failure (66.7% vs. 26.7%, p = 0.001). In the univariate and multivariate
analyses, high-flow oxygen and APACHE II score were independent predict factors to respiratory failure regression (OR = 20.381, p =
0.038; OR = 36.827, p = 0.026). Patients treated with high-flow oxygen had shorter intensive care unit stay length (19.5 ± 13.4 vs. 7.8 ±
4.7, p = 0.009) and early mortality tended to be significantly lower (17.9% vs. 40.0%, p = 0.058).
Conclusion: High-flow oxygen is a more effective method for acute pancreatitis complicated with acute respiratory dysfunction than
conventional oxygen therapy.
Key words: High-flow oxygen through nasal cannula, acute pancreatitis, respiratory dysfunction, acute respiratory distress syndrome

1.Introduction
Pulmonary complications of acute pancreatitis (AP)
characterized by increased permeability of the pulmonary
microvasculature and alveolar spaces filled with leaked
protein-rich exudate were frequent with morbidity about
75% [1,2], including acute lung injury (ALI) or ARDS,
atelectasis, pleural effusion, alteration in diaphragmatic
function, i.e. [3–5]. It usually resulted in a need for
endotracheal intubation and mechanical ventilation, in
addition, the mechanisms were complex and still to be
discovered [6]. It was reported that 30%–60% of death
was related to pancreatitis-associated ALI and ARDS
[7–9]. Furthermore, nearly one-third of death of acute
pancreatitis prior to admission to hospital were associated
with ALI [10]. Studies have revealed that acute respiratory
dysfunction (ARD) was an independent prognostic
factor for hospital mortality in severe acute pancreatitis
(SAP) along with the age, chronic health situation, and
organ failures, which was associated with 60% of death
within the first week [11,12]. Therefore, more attention
has been paid to the treatment of pancreatitis-associated

respiratory complications for reducing early death.
High-flow oxygen through nasal cannula (HFNC),
which is increasingly used in intensive care unit (ICU)
and non-ICU wards was considered as an alternative to
noninvasive positive pressure ventilation (NPPV) and
conventional oxygen therapy (COT) with better tolerated
and decreasing work of breathing [13,14]. It could provide
heated and humidified air and reduce airway secretion and
atelectasis with high-flow rates of up to 60 L/min as well as
high FiO2 from 0.21 to 1.0 [15,16]. Previous studies have
revealed that HFNC has the capability of generating low
levels of positive end-expiratory pressure and decreasing
physiological dead space through flushing expired
carbon dioxide into the upper airway [17]. It has been
applied to various diseases, including various respiratory
failure, cardiogenic pulmonary edema, postextubation,
postoperative patients, and infants [15, 16, 18–20].
However, the efficiency of HFNC in acute pancreatitis is
unclear. Our research is intended to illustrate the value
of HFNC in acute pancreatitis complicated with acute
respiratory failure.

* Correspondence: 42869775@qq.com

This work is licensed under a Creative Commons Attribution 4.0 International License.

707

JI et al. / Turk J Med Sci
2. Materials and methods
2.1. Trial design
All acute pancreatitis complicated with ARD admitted to
ICU were included in this retrospective study from January
2014 to June 2019. This trial was approved by the ethical
committee of our hospital (approval number: KY030-01) and
was registered on the Chinese Clinical Trial Registry (www.
chictr.org.cn/, registration number: ChiCTR2000029202),
and written informed consent was obtained from patients
or their families before HFNC treatment.
2.2. Patients
Computed tomography (CT) combined with supportive
specific laboratory data were used in the diagnosis of AP.
All AP were enrolled if they followed one of the following
criteria: PaO2/FiO2 < 300 mmHg; respiratory rate > 25/
min; dyspnea or accessory muscle use; asynchronous or
paradoxical breathing; required > 5 L/min O2 to maintain
SpO2 > 92%. Exclusion criteria: the need for immediate
intubation, central nervous system disorder, cannot
answer questions, contraindications for the use of the
mask (noncooperative patient). Patients were asked to
grade their dyspnea score [21] (improvement; no change;
deterioration) and comfort score [22] (poor; acceptable;
good) 1 h after the intervention.
2.3. Study intervention
All patients were treated with COT through a face mask
or nasal cannula before enrolling. In the COT group,
oxygen therapy was applied continuously through a
face mask or nasal cannula at a flow rate of up to 10
liters per minute. The rate was adjusted to obtain SpO2
> 92% until patients recovered or were intubated.
High-flow humidified oxygen (37 °C and 44 mgH2O/L)
was delivered continuously through a nasal cannula with
Optiflow (Fisher and Paykel Healthcare) with a primal
flow rate of 50 L/min, a primal FIO2 of 50%, and dynamic
adjustments to obtain SpO2 > 92%. HFNC was switched to
COT if SpO2 was ≥ 95% at ≤ 5 L/min O2 or the PaO2:FIO2
was at least 300.
Intubation and mechanical ventilation decisions were
made by the physicians with the criteria: respiratory arrest;
respiratory pauses with loss of consciousness or gasping
respiration; encephalopathy; cardiovascular instability;
unmanageable secretions; respiratory fatigue; refractory
hypoxemia (HFNC: SpO2 ≤ 88% with FIO2 = 100%; COT:
SpO2 ≤ 88% with at least 10 L/min), or respiratory acidosis
(pH < 7.30 and PaCO2 ≥ 50 mmHg).
2.4. Primary and second outcomes
The primary outcomes are the early intubation rate, defined
as a percentage of intubation and mechanical ventilation
in 10 days and the median time to intubation from
patients enrolled. The second outcome includes changes
in physiological parameters as well as arterial blood
gases and grade of dyspnea, comfort score, regression of
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respiratory failure after 1-h intervention, adverse events
(atelectasis, pleural effusion, and abdominal distension),
early mortality defined as mortality in 10 days and ICU
stay length.
3. Statistical analysis
The chi-square test or Fisher test was used in the
comparisons for categorical variables while the unpaired
student’s t-test or Mann-Whitney U test was performed
for continuous variables. The analysis of the data obtained
before and after intervention from each patient was
made with the paired Wilcoxon test. Variables associated
with respiratory failure regression were assessed by
univariate and multivariate logistic-regression analyses.
Variables suspected to be associated with regression
of respiratory failure with a P < 0.10 after univariate
analysis were accounted into the multivariate analysis.
All statistical analyses were performed using IBM SPSS,
Version 19.0 (IBM Corp., Armonk, NY, USA) or GraphPad
Prism version 6.0 (GraphPad Software Inc., San Diego,
CA, USA). A p-value (two-tailed) < 0.05 was considered
statistically significant.
4. Results
4.1. Patients
A total of eighty-one patients with AP were admitted to
ICU. Seven were intubated immediately at admission
and five did not meet the classification criteria at last.
Ultimately, sixty-nine patients were included in this
retrospective study. Thirty out of 69 were treated with
conventional oxygen through nasal cannula or face mask,
while 39 were treated with HFNC.
Baseline characteristics of patients, including
demographic data, the severity of illness (APACHE II),
etiology, the severity of AP (Ranson score and Balthazar
score), and associated comorbidities were recorded in
Table 1. Vital signs and arterial blood gases before and
after enrollment (1 h) are collected in Table 2. We also
evaluated the incidence of atelectasis and pleural effusion
in the two groups by CT.
4.2. Primary outcome
The early intubation rate was 25.6% (10 of 39 patients) in
the HFNC group, 56.7% (17 of 30) in the COT group (p =
0.013), Table 3, Figure 1. The median time to intubation
was 64.25h in the HFNC group, 7.75h in the COT
group (p < 0.001). Table 3. Meanwhile, we compared the
intraabdominal pressure (cmH2O) before intubation of
intubated patients in the two groups (HFNC 21.7 vs. COT
19.1; p = 0.103; not shown).
4.3. Changes in physiological parameters and arterial
blood gases
After 1 h of intervention, patients treated with HFNC
had decreased respiratory rate (breaths/min), heart rate
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Table 1. Patients characteristics.
HFNC
(n = 39)

COT
(n = 30)

P

<52

18(46)

18(60)

0.332

≥52

21(54)

12(40)

Men

19(49)

21(70)

Female

20(51)

9(30)

Alcoholic

6(15)

6(20)

Biliary

23(59)

12(40)

Hyperlipidemic

10(26)

12(40)

<3

20(51)

14(47)

≥3

19(49)

16(53)

<3

19(49)

15(50)

≥3

20(51)

15(50)

≤6

22(56)

14(47)

>6

17(44)

16(53)

<10

18(46)

16(53)

≥10

21(54)

14(47)

<5

15(38)

13(43)

≥5

24(62)

17(57)

Yes

14(36)

13(43)

No

25(64)

17(57)

Arterial hypertension

13(50)

9(43)

Diabetes

7(27)

7(33)

Cardiac insufficiency

6(23)

5(24)

Characteristics
Age, mean, y-no. (%)

Gender-no. (%)
0.09

Etiology of AP-no. (%)
0.285

Ranson score at admission
0.809

Ranson (48 h) score
1.000

Balthazar score
0.472

APACHE II score, mean-no. (%)
0.631

SOFA score, mean-no. (%)
0.806

Current or past smoking-no. (%)
0.621

Associated comorbidities-no. (%)
0.865

HFNC: High-flow oxygen through nasal cannula; COT: Conventional oxygen therapy

(beats/min) (27 vs. 21, p < 0.001; 121 vs. 104, p = 0.008)
and increased PaO2 (mmHg) (64 vs. 110; p < 0.001),
while PaCO2 (mmHg) and PaO2/FiO2 (mmHg) had no
changes (37 vs. 42, p = 0.087; 189 vs. 210, p = 0.539)
compared with baseline. However, in the COT group,
after 1 h of intervention, respiratory rate, heart rate, and
PaO2/FiO2 were similar (30 vs. 26, p = 0.166; 114 vs.
109, p = 0.486; 192 vs. 201, p = 0.142) with baseline,

whereas PaCO2 and PaO2 were higher (38 vs. 50; p <
0.001; 64 vs. 83; p < 0.001), Table 2.
There was no difference in physiological parameters
and arterial blood gases at baseline between the HFNC
group and the COT group. Compared with the COT
group, patients treated with HFNC had decreased
respiratory rates, PaCO2 (21 vs. 26, p = 0.020: 42 vs. 50,
p < 0.001) and increased PaO2 (110 vs. 83, p = 0.003) 1 h
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Table 2. Physiological parameters and arterial blood gases at baseline and 1 h after intervention.
Mean (95% CI)
Baseline

Parameters

1h

HFNC

COT

P

HFNC

COT

P

Pa

Pb

Pc

Heart rate, beats/min

121
(111–130)

114
(107–121)

0.286

104
(99–110)

109
(99–118)

0.417

0.008

0.486

0.023

Respiratory rate,
breaths/min

27
(25–29)

30
(26–33)

0.379

21
(19–22)

26
(23–29)

0.020

<0.001

0.166

0.011

PaCO2, mmHg

37
(34–40)

38
(35–42)

0.573

42
(40–44)

50
(45–55)

<0.001

0.087

<0.001

0.053

PaO2, mmHg

64
(62–65)

64
(60–67)

0.789

110
(99–121)

83
(79–86)

0.003

<0.001

<0.001

<0.001

PaO2/FiO2 mmHg

189
(170–208)

192
(165–219)

0.628

210
(179–240)

201
(182–220)

0.561

0.539

0.142

0.856

6(15.4)
12(30.8)
21(53.8)

5(16.7)
6(20.0)
19(63.3)

Comfort score, No. (%)
Poor
Acceptable
Good

0.596

HFNC: High-flow oxygen through nasal cannula; COT: Conventional oxygen therapy;
a: Baseline vs. 1 h in HFNC; b: Baseline vs. 1 h in COT; c: Changes in the HFNC group vs. that in the COT group 1 h after the intervention.
Table 3. Primary outcome.
Parameters

HFNC

COT

P

Intubation number no. (%)

10(25.6)

17(56.7)

0.013

Median time to intubation median ± SD, h

64.25 ± 12.71

7.75 ± 2.96

<0.001

HFNC: High-flow oxygen through nasal cannula; COT: Conventional oxygen therapy

after intervention. Patients showed greater improvement
in PaO2 in the HFNC group than that in the COT group
(p < 0.001), Table 2.
4.4. Dyspnea grade, comfort score, and respiratory
dysfunction regression
The comfort score was similar between the two groups
(p = 0.596, Table 2). There was a higher proportion of
patients feeling improvement in dyspnea in the HFNC
group (87.2% vs. 56.7%, p = 0.006), Figure 2.
Improved respiratory dysfunction was defined as
respiratory rate <25/min and improvement in breathing
effort, including accessory breathing muscle activity
and/or paradoxical breathing. Finally, 34 out of 69
patients (26 in the HFNC group vs 8 in the COT group;
p = 0.001; Figure 3) got respiratory failure regression
1 h after intervention. In the univariate analysis, the
following parameters were associated with respiratory
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failure improvement: APACHE II score, PaO2 at
baseline, and Oxygen strategies. Higher APACHE II
score, lower PaO2 at baseline and conventional oxygen
therapy exhibited an increased risk for poorer regression
of respiratory failure (OR = 12.250, 95% CI 1.268–
118.361, p = 0.030; OR = 8.000, 95% CI 1.252–51.137, p
= 0.028; OR = 6.429, 95% CI 1.026–40.261, p = 0.047).
In multivariate logistic-regression analyses, HFNC, and
APACHE II score were independent predict factors to
regression of respiratory failure (OR = 20.381, 95% CI
1.177–351.911, p = 0.038; OR = 36.827, 95% CI 1.529–
887.083, p = 0.026), Table 4.
4.5. Adverse events and clinical outcomes
No significant differences were found for adverse events
between the two groups. Early mortality in the HFNC
group had a trend to be significantly lower than that in
the COT group (17.9% vs. 40.0%, p = 0.058). Patients
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Figure 1. Comparison of intubation rate between the two
groups. HFNC: High-flow oxygen though nasal cannula; COT:
Conventional oxygen therapy

Figure 2. Comparison of dyspnea score improvement between
the two groups 1 h after intervention. HFNC: High-flow oxygen
through nasal cannula; COT: Conventional oxygen therapy

treated with COT had much longer ICU stay length
(19.5 ± 13.4 vs. 7.8 ± 4.7, p = 0.009), Table 5.
5. Discussion
Accumulating research have revealed some advantages of
HFNC application in pneumonia-associated respiratory
dysfunction, including decreased intubation rate, lower 90day mortality, and increased ventilator-free days compared
with NPPV and/or COT [23–26]. Despite this, COT with
a face mask or nasal cannula is still the first-line treatment
for those lacking studies about HFNC application in APassociated respiratory dysfunction. However, COT is
not able to satisfy some patients with severe hypoxemia.
Therefore, to our knowledge, this study illustrated the
efficiency of HFNC in acute pancreatitis complicated
with acute respiratory dysfunction for the first time.
In this study, eliminating the effect of secondary infection
on intubation, we compared the early intubation rate

Figure 3. Comparison of respiratory failure regression between
the two groups 1 h after intervention. HFNC: High-flow oxygen
through nasal cannula; COT: Conventional oxygen therapy

and the median time to intubation of the two groups in
combination with the pathophysiological characteristics
of pancreatitis. Severe acute pancreatitis has two
representative phases. The first stage is in the first ten days,
with characteristics of the systemic inflammatory response
syndrome (SIRS). The second usually comes up during the
second week and is marked by infectious manifestations
[27]. In the end, we found patients in the HFNC group had
a lower early intubation rate and a longer median time to
intubation.
We also compared other outcomes, including changes in
physiological parameters and arterial blood gases, comfort
score, regression of dyspnea and respiratory dysfunction,
adverse events, early mortality, and ICU stay length between
the two groups and found that first, HFNC was superior
to COT in improving dyspnea, decreasing respiratory rate
and heart rate, preventing carbon dioxide retention, and
had a stronger effect on improving PaO2. However, we did
not find a difference in PO2/FiO2 between the two groups,
indicating that HFNC could improve PO2 with higher
FiO2, but it could not improve physiopathologic changes.
Second, HFNC was independently associated with the
regression of respiratory dysfunction. Third, the comfort
score of HFNC was similar to that of COT. At last, patients
treated with HFNC had shorter ICU stay length and lower
early mortality. We hypothesize that the reason why the
early mortality between the two groups did not reach
statistical significance would be due to the limited number
of patients in our study. Above all, we would come to the
conclusion that HFNC is prior to COT in acute pancreatitis
complicated with acute respiratory dysfunction.
There are some limitations to our reach. First, this study
is a single-center with a small number of patients. Second,
we did not compare HFNC and NPPV. Hence, in the
future, we should compare HFNC, NPPV, and COT in
multicenter studies with large samples.
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Table 4. Univariate and multivariate analysis of risk factors to regression of respiratory failure.
Univariate analysis
Variables

Odds ratio IC (95%)

Age, mean, y
<51 ≥51
Gender
Men/Female
Etiology of AP
Alcoholic
Biliary
Hyperlipidemic
Ranson score at admission
<3, ≥3
Balthazar score
≤6, >6
APACHE II score, mean
<10, ≥10
SOFA score, mean
<5, ≥5
Current or past smoking
Clinical parameters at baseline, median
Heart rates, beats/min
<116, ≥116
Respiratory rate, breaths/min
<29, ≥29
Arterial blood gas at baseline, median
PaCO2, mmHg
<38, ≥38
PaO2, mmHg
<63, ≥63
PaO2/FiO2, mmHg
<181, ≥181
Oxygen strategies, no. (%)
High-flow oxygen/Conventional oxygen therapy

3.6

0.591–21.932

0.720

0.137–3.784

3.250
0.208

0.163–64.614
0.017–2.518

4.333

0.708–26.531

2.407

0.456–12.720

12.250

1.268–118.361

1.050
1.050

0.197–5.602
0.197–5.602

1.200

0.237–6.065

0.415

0.079–2.195

0.833

0.165–4.212

8.000

1.252–51.137

1.389

0.264–7.299

6.429

1.026–40.261

Multivariate analysis
P

Odds ratio IC (95%)

P

36.827

0.026

0.165
0.698
0.157
0.440
0.217
0.113
0.301
0.030

1.529–887.083

0.954
0.954
0.825
0.301

0.825
0.028

0.518–75.960

6.275

0.698
0.047

20.381

1.177–351.911

Table 5. Adverse events and clinical outcomes.
Group
Events

P

COT (n = 30)

HFNC (n = 39)

Atelectasis-no. (%)

24(80.0)

30(76.9)

1.000

Pleural effusion-no. (%)

22(73.3)

26(66.7)

0.606

Abdominal distension-no. (%)

12(40.0)

14(35.9)

0.804

Early mortality-no. (%)

12(40.0)

7(17.9)

0.058

ICU stay length, median ± SD, d

19.5 ± 13.4

7.8 ± 4.7

0.009

HFNC: High-flow oxygen through nasal cannula; COT: Conventional oxygen therapy
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